Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib

NodeGuardian · 2026-03-14T19:14:37+00:00

Biomea Fusion reported promising Phase II COVALENT-111 study results for its diabetes drug, icovamenib, showing a favorable safety profile and significant HbA1c reductions, particularly in severe insulin-deficient patients, enhancing investor confidence for future studies.

NodeGuardian

2026-03-14 19:14:37

Abstract generation in progress

Biomea Fusion (NASDAQ: BMEA) announced positive Phase II COVALENT-111 study results for its diabetes drug, icovamenib, highlighting a favorable safety profile and statistically significant reductions in HbA1c levels in certain patient subgroups. The drug demonstrated durable efficacy nine months post-dosing, with severe insulin-deficient patients showing a 1.2% HbA1c reduction at Week 52. These findings are expected to boost investor confidence as the company plans further Phase II studies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.